CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-12 | CRAVES FRED B Director | Sale | −800 | $333.66 | $267K | 350,276 |
| 2025-03-12 | CRAVES FRED B Director | Sale | −200 | $334.97 | $67K | 350,076 |
| 2025-03-12 | CRAVES FRED B Director | Option exercise · Stock Option (Right to Buy) | −1,728 | 7,742 | ||
| 2025-03-12 | CRAVES FRED B Director | Option exercise · Stock Option (Right to Buy) | −6,000 | 0 | ||
| 2025-03-10 | Dier Mardi SVP and CFO | Sale 10b5-1 | −258 | $323.04 | $83K | 10,440 |
| 2025-03-10 | FOUSE JACQUALYN A Director | Grant or award | +894 | 894 | ||
| 2025-03-10 | FOUSE JACQUALYN A Director | Grant or award · Stock Option (Right to Buy) | +1,579 | 1,579 | ||
| 2025-03-05 | Sibold William John President and CEO | Grant or award | +13,066 | 117,369 | ||
| 2025-03-05 | Sibold William John President and CEO | Grant or award · Stock Option (Right to Buy) | +22,009 | 22,009 | ||
| 2025-03-05 | Dier Mardi SVP and CFO | Grant or award | +3,784 | 10,698 | ||
| 2025-03-05 | Dier Mardi SVP and CFO | Grant or award · Stock Option (Right to Buy) | +6,374 | 6,374 | ||
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +6,825 | $87.92 | $600K | 10,553 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +7,288 | $87.09 | $635K | 17,841 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −900 | $335.15 | $302K | 16,941 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,777 | $336.78 | $598K | 15,164 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,146 | $338.09 | $387K | 14,018 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −400 | $339.68 | $136K | 13,618 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,657 | $340.75 | $565K | 11,961 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,043 | $341.84 | $357K | 10,918 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,077 | $342.90 | $369K | 9,841 |
Page 24 of 82 · 1,629 trades